DMKC Advisory Services LLC Acquires 10,679 Shares of Pfizer Inc. $PFE

DMKC Advisory Services LLC increased its holdings in Pfizer Inc. (NYSE:PFE) by 18.3% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 69,020 shares of the biopharmaceutical company’s stock after purchasing an additional 10,679 shares during the quarter. DMKC Advisory Services LLC’s holdings in Pfizer were worth $1,697,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in the business. GKV Capital Management Co. Inc. bought a new stake in Pfizer in the first quarter valued at approximately $27,000. North Capital Inc. purchased a new position in shares of Pfizer in the first quarter worth $28,000. Bayforest Capital Ltd bought a new stake in Pfizer during the 1st quarter valued at $28,000. Horizon Financial Services LLC bought a new position in Pfizer during the 1st quarter valued at approximately $35,000. Finally, WPG Advisers LLC bought a new stake in Pfizer in the first quarter valued at $35,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Stock Performance

PFE opened at $27.21 on Thursday. The company has a market cap of $154.68 billion, a P/E ratio of 14.47, a price-to-earnings-growth ratio of 0.82 and a beta of 0.55. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The firm’s 50-day moving average price is $24.59 and its 200-day moving average price is $24.14. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $30.43.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.58 by $0.20. The company had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm’s revenue was up 10.3% on a year-over-year basis. During the same period in the prior year, the company earned $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, equities analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently commented on the stock. Citigroup boosted their price objective on shares of Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 6th. Morgan Stanley boosted their price objective on shares of Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a research report on Wednesday, August 6th. Bank of America lifted their target price on Pfizer from $27.00 to $28.00 and gave the company a “neutral” rating in a research report on Wednesday, August 6th. Wall Street Zen lowered Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday. Finally, UBS Group reiterated a “neutral” rating and issued a $28.00 price target on shares of Pfizer in a research note on Wednesday. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Pfizer currently has a consensus rating of “Hold” and an average price target of $28.29.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.